ARTICLE | Clinical News
Sparsentan: Phase II data
September 12, 2016 7:00 AM UTC
Top-line combined data from the 3 sparsentan cohorts in the double-blind, international Phase II DUET trial in 96 evaluable patients with focal segmental glomerulosclerosis showed that once-daily oral...